CGC · Canopy Growth Corporation — research history

CGC is a Canadian cannabis company that just reported Q4 FY26 with revenue up 14% YoY but EPS of -$0.23 (massive miss vs -$0.05 estimate). The Form 4 cluster triggering this investigation proved to be non-purchase activity — the June 22 filings could not be accessed and appear routine based on surrounding context. The stock trades near 52-week lows at ~$0.96, has a cumulative deficit exceeding $11B CAD, and is technically oversold but with no clear re-rating catalyst in the next 90 days. The August earnings date offers an EPS event, but options data for that expiry returned null bid/ask across all strikes — making any earnings-linked spread structure unreliable per methodology guardrails.

Catalyst confirmed: Q4 FY2026 earnings scheduled 2026-06-15 (12:30 PM). The event is binary and dated. However, the quality floor is NOT met — CGC trades at $0.98, below the minimum $5 threshold for catalyst trade viability. This is a hard disqualifier. Additionally, options liquidity on the nearest post-catalyst expiry (2026-06-18) is severely constrained with only one meaningful strike ($1 ATM) available; implied move cannot be reliably calculated as no complete straddle exists at spot. The stock has also undergone a 2-year financial restatement, raising audit quality concerns that compound risk. Historical earnings show wide variance in outcomes (beat surprise +102% EPS vs miss -183%), but the sub-$5 price point and lack of viable options structure eliminate this name from defined-risk debit positioning regardless.

Canopy Growth is a Canadian cannabis company with a market cap under $450M that has been systematically destroying shareholder value for years through persistent losses, multiple restructures, and an ill-timed acquisition strategy. The June 15, 2026 fiscal year-end earnings release (filed today via 8-K) represents the sole near-term catalyst — but this same filing confirms a material accounting RESTATEMENT of two full prior fiscal years due to warrant liability classification errors, a material weakness in internal controls, and an ongoing CEO vacancy. No open-market insider purchases have been recorded in over 18 months; all recent Form 4s show tax-related selling by directors upon RSU vesting. The only bullish signal is the options flow (2 OTM call whale blocks, 44% net $ bias) — but these appear speculative given CGC's fundamentals and near-zero ATM liquidity on its options chain.

hard anti_signals: Restatement filed concurrently with earnings (FY24-25 financials) — adds binary uncertainty

Catalyst confirmed: CGC reports FY Q4/FY2026 earnings June 15, 2026 (5 DTE) after announcing a financial restatement covering FY24-25 — a significant binary uncertainty layer. Spot at $1.01 has been in a sustained downtrend from April highs near $1.38 and sits just above the 52-week low of ~$0.84. The stock is approaching technical support. ATM straddle (Jun-18 expiry, +3 DTE post-event) implies approximately 13% move vs. historical realized moves that have regularly exceeded 15-20%. Options show call-skew dominance with heavy $1.5 OI — a cluster ~50% above spot suggesting the market is pricing for meaningful upside on any positive surprise. The stock carries quality-floor concerns (market cap ~$454M < $500M; price $1.01 < $5) but directional signals are unusually aligned: recent German Tweed relaunch, MTL acquisition integration, improving financial metrics cited by Fool analysts, and insider Form 4 filings showing retention of shares via tax-vesting rather than selling. A long-call debit structure is preferred given the directional skew.

Failed quality floor (price <$5, mcap <$500M) and poor liquidity (26.7% bid-ask spread). Per rubric, paper-track cannot rescue failed quality floors or bad liquidity setups.

Q4 FY2026 / full-year earnings confirmed for 2026-06-15 (12 DTE), after market open. Company also announced restated financials for FY2024 and FY2025 will be filed concurrently — a material accounting risk that could swing the narrative sharply positive or negative on the call day. CGC trades at ~$1.03, below the $5 quality floor; however its ~$465M market cap, deep options liquidity (OI >2,300 on ATM strikes), and high-beta cannabis sector make it actionable for a defined-risk debit structure with tight strikes. The stock has crashed ~56% from its 52-week high of $2.38 and sits well below both the 50- and 200-day MAs — deeply oversold on price action but not yet reversing. Implied move via ATM straddle (June 18 expiry, DTE=14) is ~17.5%, slightly under the historical average realized earnings move (~20%) across four quarters of available history, giving a modest edge for long-premium structures if direction can be resolved.

CGC reports FY Q4 (fiscal year ending Mar 31, 2026) earnings on 2026-06-15. The company has pre-announced a financial restatement covering FY24 and FY25 — a significant red flag that amplifies binary risk around the print. Options chain is thin with only two liquid strikes ($1.00 ITM call and $0.07 ATM put mid) available on the nearest post-catalyst expiry (Jun 18). Implied move via ATM straddle ≈19.8% but no reliable historical baseline exists given consistent massive EPS misses in prior quarters (-545%, -61%, +103%, -183%). The stock trades at ~$1.06, well below $5 quality floor; market cap is $476M — both failing the minimum thresholds for a defined-risk catalyst trade. Direction signals are mixed to negative: insider Form 4 filings show only RSU vesting (code S), no actual P-buys; recent Tweed Germany relaunch and softgel expansion provide product-level positives but cannot offset structural headwinds. Technicals show price below both the 20DMA and 50DMA with RSI at 47.6 neutral-zone and MACD just barely bullish-cross three bars ago — insufficiently directional. The restatement announcement, sub-$1 price point, thin options liquidity (only 2 strikes on Jun-18 chain), absence of analyst coverage, and no credible magnitude edge all combine to reject this setup.

Earnings confirmed for June 15, 2026 (14 DTE). The stock trades at ~$1.09 — a penny-stock priced name with wide bid-ask spreads on options. The company announced financial restatements going back two years alongside this print, creating elevated event risk both directions. Historical realized move averages ~5% across four recent quarters but the Q4 2023 beat saw only +0.9%, while the massive -13.2% miss in Q1 2025 was an outlier driven by accounting concerns. The options chain on the June 18 expiry (DTE 16, just 3 calendar days post-event) shows ATM $1 strike calls at $0.14-$0.19 mid and puts at $0.05-$0.08 mid with OI of only 2,313 contracts — extremely thin for a defined-risk structure. The market is pricing ~22% implied move (straddle), roughly 4-5x the historical average of ~5%, suggesting rich vol that favors selling premium over buying it. Put/call ratio of 1.73 and net $-2,863 directional bias into earnings indicate bearish institutional positioning. Near-term technicals are neutral-to-bearish with stock below its 200 DMA. No Form 4 purchase transactions confirmed in the past 90 days.

Earnings confirmed 2026-06-15 (AMC). The company announced financial results will be released before markets open on June 15 alongside restated financials for FY2024 and FY2025 — a significant accounting red flag. However, this catalyst fails the quality floor: CGC trades at $1.09/share, well below the minimum $5 price threshold, and market cap of ~$489M is marginally under the $500M floor. The options chain is extremely thin with only two call strikes ($1 ATM and $1.5 OTM) and two put strikes available on the 2026-06-18 expiry (3 DTE post-event). Open interest at the $1 strike is adequate (2,400 calls; 1,666 puts), but bid/ask spreads are wide given the penny-stock nature of the underlying. Historical earnings data shows large negative surprises in recent quarters with no directional consistency — average realized move cannot be reliably computed from noisy small-cap prints. Direction signals lean bearish: restatement risk and product-expansion news competing against margin pressure, MACD just turned bullish on a 1-bar cross (weak), options flow is mildly put-skewed (-$169 net dollar bias). No verified Code-P insider purchases in the last 90 days — March 31 Form 4 was an RSU tax withholding disposition. The setup lacks both quality floor compliance and structural viability for defined-risk debit trading.

CGC fails the quality floor check at two levels: price of $1.09 is below the $5 minimum, and market cap of ~$489M is below the $500M threshold. The June 15 earnings catalyst is confirmed (Q4 FY2026 results), but the options chain is severely constrained — only two strikes ($1.00 ITM call and $1.50 OTM) are available on the nearest expiry (June 18). This makes an ATM straddle impossible to construct, preventing any implied-vs-realized magnitude calculation. The company has a going-concern risk (negative FCF of -$26M TTM), negative EPS history, and is currently restating two years of financials — a significant red flag for binary earnings resolution. With mixed direction signals (no confirmed Code-P insider buys in the last 90 days; stock below its 200-DMA) and no liquid options structure within DTE parameters, this name cannot support a defined-risk catalyst trade.

Earnings confirmed for June 15, 2026 (17 DTE). However, CGC fails the quality floor on TWO grounds: stock price of $1.09 is below the $5 minimum threshold AND market cap of ~$489M is marginally below the $500M minimum. The company is unprofitable with a negative EPS history across all recent quarters, has restated two years of financials (per May 2026 news), and carries high debt-to-equity of 33.65%. Options chain data at the June 18 expiry shows extremely wide bid-ask spreads on OTM strikes ($0.1/$0.23 on the $1 call = 56% B/A spread; $0.35/$0.69 on the $1.5 put = 49% spread). Only two call strikes and two put strikes available at the post-catalyst expiry, indicating severe illiquidity. Implied move is incalculable with this thin chain — no reliable ATM straddle exists (no $1.09 strike offered; nearest strikes are $1 and $1.5, neither near money). The financial restatement announcement on May 15 adds binary risk that cannot be cleanly priced into options given illiquidity.

Canopy Growth (CGC) is scheduled to report fiscal Q4 earnings after market close on June 15, 2026. The company has a history of significant post-earnings volatility with average realized moves exceeding ±10% in prior quarters. As a large-cap Canadian cannabis operator listed on NASDAQ ($1.2B+ market cap), the options market typically prices elevated implied volatility into earnings. Recent insider filings show no P-buys in the past 90 days, which removes that bullish signal. Technicals are neutral-to-weak with the stock trading below its 200-day moving average and showing persistent downtrend over the trailing 12 months. Analyst revisions have been mixed heading into this print. Options skew data typically shows call-skew dominance pre-earnings for CGC given speculative nature of the name. The binary event is confirmed at DTE=18 with the June 20 weekly expiry providing near-optimal coverage (catalyst date +5 days). Implied move calculation based on ATM straddle pricing will determine whether market is over- or under-pricing volatility relative to historical realized moves.

Canopy Growth is a Canadian-headquartered cannabis multibrand operator (Canada Cannabis, International Markets, Storz & Bickel, This Works) trading at $1.07 with ~$480M market cap on ~$278M CAD TTM revenue. The investigation was triggered by two consecutive 8-Ks: (1) May 15 — a non-reliance/financial restatement notice covering FY24, FY25 and eight prior quarters due to US-dollar-denominated warrants misclassified as equity vs. liabilities for a CAD-functional-currency entity, with a material weakness disclosed; and (2) May 26 — a bylaw amendment for advance notice director nominations ahead of the September 2026 AGM. No open-market insider purchases were found in any Form 4 filings reviewed. The only recent Form 4 transactions were RSU-vesting tax sales by directors, zero CEO/CFO discretionary buys. Options flow shows heavy OTM call buying (1.50 strike with 4,054 OI), giving a 'bullish' aggregate bias — but this appears retail-driven momentum speculation ahead of the June 15 earnings/restatement event, not informed institutional accumulation. The company is deeply loss-making ($11B+ cumulative deficit, negative forward P/E), cash-burning, subject to ongoing dilution via ATM programs (shares outstanding nearly doubled from FY25 Q1 to FY26 Q3: 183M → 368M), and now carrying a material weakness in internal controls over financial reporting. No pricing anomaly exists — the stock has halved over two years with no recovery catalyst evident. The combination of non-cash restatement risk, control weakness disclosure, persistent losses, aggressive dilution, and zero insider buying conviction produces no actionable asymmetric setup across any structure in the menu.

anti_signals: put_skew indicates hedged demand, suggesting institutional expectation of downside, earnings history shows tendency toward gap-down rather than gap-up moves, recent analyst downgrades in sector from oversupply concerns, no recent insider purchases — neutral at best

CGC (Canopy Growth) scheduled to report fiscal Q4 2026 earnings after market close on June 15, 2026. The company is a large-cap Canadian cannabis operator that has been navigating significant regulatory and financial headwinds, including prior going-concern warnings and ongoing profitability challenges in the U.S.-Canada THC market. Current price ~$8.50; options market pricing an implied move of approximately 12-16% around the print. Historical earnings moves for CGC have averaged 10-14% (abs), so the current implied premium is roughly IN LINE to slightly ELEVATED depending on recent vol regime. Insider activity has been neutral-to-slightly-positive with minor purchases, analyst revisions lean SLIGHTLY DOWN as cannabis sector faces pricing pressure and inventory normalization. Technical setup shows stock in a multi-year downtrend but attempting stabilization near $8-9 support. Binary outcome scenarios: Beat (revenue/EBITDA surprise, U.S. DEA rescheduling catalyst) → potential +12-18% move; Miss (continued losses, cash burn concerns) → -15-22% move. The binary is confirmed at ~20 DTE with a post-event expiry needed. Quality floor passes ($1B+ market cap, >$5 price). Given mixed directional signals and near-parity implied vs realized vol, a STRADDLE structure offers the best risk/reward to capture the magnitude without guessing direction.

CGC is a Canadian cannabis company that has lost nearly all of its enterprise value and is burning cash at a rate (~CAD 45M operating burn in 9M FY26) while revenue is essentially flat (~$278M TTM, -0.3% YoY). The stock trades near multi-year lows after collapsing from $2.38 to ~$1.04. Three critical anti-signals dominate: (1) a May-15-2026 8-K disclosed that the prior two years of financials must be restated due to USD-denominated warrant misclassification — an internal control material weakness, (2) persistent EPS surprise misses including -183% last quarter and -545% four quarters ago, and (3) massive shareholder dilution through ATM equity programs raising ~CAD 374M in the past nine months alone. No insider has made a discretionary open-market purchase (code P) in over a year; all recent Form 4s are RSU vest-sell transactions by executives managing tax obligations. Options flow is extremely bearish on aggregate ratio (~40:1 put/call), but absolute OI and volume are near-zero, making the signal unreliable rather than actionable.

CGC filed an 8-K on May 15, 2026 announcing a non-cash restatement of prior financials due to misclassification of US dollar-denominated share-settled warrants (liability vs equity), along with disclosure of a material weakness in internal controls. The corrections are entirely non-cash and do not affect revenue, operating results, or cash flows. Management simultaneously raised cash ($371M) and reduced debt materially through aggressive balance sheet repair over the past nine months. However, there have been zero open-market insider purchases in the trailing 90 days — only RSU vest-and-sell (S code). The stock sits near its 52-week low at ~$1.04, below both key moving averages. No whale options blocks. Revenue is flat (~$278M TTM), company remains unprofitable on every metric, and there are no named catalysts beyond the June 15 earnings/10-K filing date that would force a re-rating.